Previous 10 | Next 10 |
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2020 Q2 earnings Read more ...
IVERIC bio, Inc. (ISEE) Q2 2020 Earnings Conference Call August 5, 2020, 08:00 AM ET Company Participants Kathy Galante - IR Glenn Sblendorio - President and CEO Dave Carroll - CFO Pravin Dugel - Chief Strategy and Business Officer Kourous Rezaei - Chief Medical Officer Co...
IVERIC bio (NASDAQ: ISEE ) : Q2 GAAP EPS of -$0.32 misses by $0.01 . More news on: IVERIC bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Conference Call and Webcast Today, August 5, 2020, at 8:00 a.m. ET - IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update. “Following the positive results f...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10 a.m. Eastern Time. ...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020. Following the announcement, the IVERIC bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to disc...
– A Biotechnology Industry Leader and Internationally Known Vitreo-Retinal Specialist with Notable Expertise in Pharmaceuticals for Age-Related Macular Degeneration and Ocular Gene Therapy – IVERIC bio, Inc. (NASDAQ: ISEE) announced today the election of Mark S. Blu...
Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of Zimura Iveric Bio ( ISEE ) announced that it has dosed the first patients for its second pivotal Phase 3 clinical trial GATHER2. The study seeks to evaluate Zimura’s potential for treating patients with geographic atrophy ...
The first patient has been dosed in a second pivotal clinical trial, Phase 3 GATHER2 , evaluating IVERIC bio's (NASDAQ: ISEE ) Zimura (avacincaptad pegol), a complement C5 inhibitor, in patients with geographic atrophy (GA) secondary to age-related macular degeneration. More news o...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) second...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...